Stryker Corporation (SYK)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-15

$294.66+0.49%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Stryker Corporation’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.3%

+10% or more+5%0%−5%−10% or less

16.74 → 16.69 EPS · FY ending Dec 31, 2027 · 16 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 16; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain adjusted EPS near $15 in 2026	A primary condition in Stryker Corporation's published investment case. The stated target is $14.90 to $15.10 EPS.	Intact	Adjusted EPS falls below $14.90 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Effectively address cybersecurity incident	A supporting condition in Stryker Corporation's published investment case. The stated target is No material operational disruption from cybersecurity issues.	Intact	Material operational disruption or new cybersecurity incidents occur	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain organic net sales growth near 8.75% in 2026	A primary condition in Stryker Corporation's published investment case. The stated target is 8.0% to 9.5% YoY revenue growth.	Under Pressure	YoY revenue growth falls below 8.0% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 of last 8 quarters. Organic net sales grew from 10.2% in 2024-Q4 to 9.0% in 2026-Q2, with consistent double-digit growth in most quarters. Management has consistently emphasized growth at the high end of MedTech, and the trajectory shows sustained strong organic sales growth delivering on this priority. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$16.69

$16.72 → $16.69 · observed estimates

FY2027 revenue$29.54B

$29.59B → $29.54B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$16.72	$29,588,964,350	26 / 26
2026-07-25	$16.72	$29,588,964,350	26 / 26
2026-07-26	$16.72	$29,601,278,981	15 / 20
2026-07-27	$16.72	$29,588,887,430	26 / 26
2026-07-28	$16.72	$29,601,278,981	15 / 20
2026-07-29	$16.73	$29,602,275,082	16 / 20
2026-07-30	$16.73	$29,590,298,170	27 / 27
2026-07-31	$16.75	$29,617,256,701	16 / 20
2026-08-01	$16.75	$29,617,256,701	16 / 20
2026-08-02	$16.76	$29,599,464,520	27 / 27
2026-08-03	$16.76	$29,599,464,520	27 / 27
2026-08-04	$16.77	$29,611,673,523	15 / 20
2026-08-05	$16.76	$29,678,514,690	27 / 27
2026-08-06	$16.77	$29,611,673,523	15 / 20
2026-08-08	$16.77	$29,611,673,523	15 / 20
2026-08-09	$16.77	$29,611,673,523	15 / 20
2026-08-10	$16.76	$29,681,085,670	27 / 27
2026-08-12	$16.77	$29,611,673,523	15 / 20
2026-08-13	$16.76	$29,681,085,670	27 / 27
2026-08-14	$16.77	$29,611,673,523	15 / 20
2026-08-15	$16.77	$29,611,673,523	15 / 20
2026-08-16	$16.77	$29,611,673,523	15 / 20
2026-08-17	$16.77	$29,611,673,523	15 / 20
2026-08-18	$16.77	$29,611,673,523	15 / 20
2026-08-19	$16.77	$29,611,673,523	15 / 20
2026-08-20	$16.76	$29,697,631,394	16 / 20
2026-08-21	$16.76	$29,697,631,502	16 / 20
2026-08-22	$16.76	$29,697,631,502	16 / 20
2026-08-23	$16.76	$29,697,631,502	16 / 20
2026-08-24	$16.76	$29,697,631,502	16 / 20
2026-08-25	$16.76	$29,697,631,502	16 / 20
2026-08-26	$16.76	$29,697,631,502	16 / 20
2026-08-27	$16.76	$29,697,631,502	16 / 20
2026-08-28	$16.76	$29,697,631,502	16 / 20
2026-08-29	$16.76	$29,697,642,781	16 / 20
2026-08-30	$16.76	$29,697,642,781	16 / 20
2026-08-31	$16.76	$29,697,642,781	16 / 20
2026-09-01	$16.76	$29,697,642,781	16 / 20
2026-09-02	$16.76	$29,697,642,781	16 / 20
2026-09-03	$16.76	$29,697,642,781	16 / 20
2026-09-04	$16.76	$29,697,642,781	15 / 20
2026-09-05	$16.76	$29,697,642,781	15 / 20
2026-09-06	$16.76	$29,697,642,781	15 / 20
2026-09-07	$16.76	$29,697,642,781	15 / 20
2026-09-08	$16.76	$29,697,642,781	15 / 20
2026-09-09	$16.75	$29,679,001,636	15 / 20
2026-09-10	$16.75	$29,674,481,570	15 / 20
2026-09-11	$16.75	$29,662,201,805	15 / 20
2026-09-12	$16.75	$29,662,201,805	15 / 20
2026-09-13	$16.75	$29,662,201,805	16 / 20
2026-09-14	$16.75	$29,662,201,805	16 / 20
2026-09-15	$16.74	$29,659,190,977	16 / 20
2026-09-16	$16.74	$29,659,230,977	16 / 20
2026-09-17	$16.74	$29,645,112,157	16 / 20
2026-09-18	$16.74	$29,645,112,157	16 / 20
2026-09-19	$16.74	$29,645,112,157	16 / 20
2026-09-20	$16.74	$29,644,592,157	16 / 20
2026-09-21	$16.74	$29,644,592,157	16 / 20
2026-09-22	$16.73	$29,632,232,157	16 / 20
2026-09-23	$16.73	$29,623,990,968	16 / 20
2026-09-24	$16.73	$29,623,990,968	16 / 20
2026-09-25	$16.73	$29,623,990,968	16 / 20
2026-09-26	$16.73	$29,615,466,968	16 / 20
2026-09-27	$16.73	$29,615,466,968	16 / 20
2026-09-28	$16.73	$29,615,466,968	16 / 20
2026-09-29	$16.73	$29,615,466,968	16 / 20
2026-09-30	$16.73	$29,615,466,968	16 / 20
2026-10-01	$16.72	$29,610,266,968	16 / 20
2026-10-02	$16.72	$29,608,414,968	16 / 20
2026-10-03	$16.72	$29,608,414,968	16 / 20
2026-10-04	$16.72	$29,608,414,968	16 / 20
2026-10-05	$16.72	$29,608,414,968	16 / 20
2026-10-06	$16.71	$29,592,894,968	16 / 20
2026-10-07	$16.71	$29,565,674,676	16 / 20
2026-10-08	$16.70	$29,559,594,676	16 / 20
2026-10-09	$16.70	$29,559,600,508	16 / 20
2026-10-10	$16.70	$29,559,600,508	16 / 20
2026-10-11	$16.70	$29,551,280,508	16 / 20
2026-10-12	$16.70	$29,551,280,508	16 / 20
2026-10-13	$16.69	$29,535,913,850	16 / 20
2026-10-14	$16.70	$29,527,995,655	16 / 20
2026-10-15	$16.69	$29,535,913,850	16 / 20

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	22	7
2026-06-01	21	7
2026-07-01	23	6
2026-08-01	23	6
2026-09-01	22	6
2026-10-01	23	6

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 23 Buy / Strong Buy · 6 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades5 maintains

Recent actions · Sep 16–Oct 15 · 5 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BTIGOct 12 · prior Jul 31

$358.00 → $316.00-11.7%

Truist FinancialOct 6 · prior May 4

$330.00 → $310.00-6.1%

BarclaysOct 6 · prior May 4

$394.00 → $375.00-4.8%

Stifel NicolausSep 30

$330.00New observation · no comparable prior

Canaccord GenuitySep 18

$385.00New observation · no comparable prior

$0$216.70$433.40

0 raises · 3 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain adjusted EPS near $15 in 2026Direct metric needs a verified mapping
Effectively address cybersecurity incidentQualitative condition
Maintain organic net sales growth near 8.75% in 2026Published status: Under Pressure

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-30.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Stryker Corporation outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder in the MedTech sector. The current thesis state is intact, supported by strong organic sales growth and consistent earnings per share (EPS) improvement.

What's priced into Stryker Corporation

The market appears to price SYK as relatively cheap compared to its peers, with a slight expectations gap. There is low fragility in execution quality, suggesting that the current valuation reflects a justified stance.

What the fundamentals likely do

Management is focused on maintaining strong organic sales growth and EPS guidance, which have shown positive trends. Recent financial performance has been strong, but there is a moderate risk of missing expectations due to industry trends.

What Stryker Corporation hinges on

The long-term thesis hinges on maintaining guidance and growth in a potentially challenging economic environment. Key factors include the performance of sector bellwethers and the impact of any guidance cuts or economic downturns.